Loading organizations…
medical company
Fibronostics develops LIVERFASt™, a blood-based non-invasive test that assesses liver fibrosis, steatosis, and MASH (NASH) activity by combining 10 biomarkers with patient data, without requiring a liver biopsy. Headquartered in New Orleans, USA, with operations in Singapore, the company has conducted over 1.9 million tests in more than 50 countries.
Fibronostics develops LIVERFASt™, a blood-based non-invasive test that assesses liver fibrosis, steatosis, and MASH (NASH) activity by combining 10 biomarkers with patient data, without requiring a liver biopsy. Headquartered in New Orleans, USA, with operations in Singapore, the company has conducted over 1.9 million tests in more than 50 countries.